We serve Chemical Name:Difluoroacetic acid CAS:381-73-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Difluoroacetic acid
CAS.NO:381-73-7
Synonyms:MFCD00004220;EINECS 206-839-0;Acetic acid, 2,2-difluoro-;UNII:ZQK1C95K3N;Difluoroacetic acid;QVYFF;2,2-Difluoroacetic acid;2,2-Difluoroethanoic acid
Molecular Formula:C2H2F2O2
Molecular Weight:96.033
HS Code:29159080
Physical and Chemical Properties:
Melting point:-1 °C
Boiling point:136.1±25.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.314
PSA:37.30000
Exact Mass:96.002289
LogP:0.22
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3265 8/PG 2
Packing Group:II
Contact us for information like MFCD00004220 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,2-Difluoroethanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00004220 Use and application,MFCD00004220 technical grade,usp/ep/jp grade.
Related News: Though the program obtained priority review from FDA back in November, analysts expressed skepticism in July 2020 after it failed to prove superior to the companies’ other drug Lumizyme in improving respiratory function in a Phase III trial. cesium phenylacetate manufacturers Expedite biocatalysis development by partnering with an API CDMO 1-(indolin-6-yl)-N,N-dimethylmethanamine dihydrochloride suppliers Sales for Tafinlar and Mekinist, the MEK inhibitor it was approved with, hit $672 million in 2016. Fast forward to 2020 and the duo generated $1.5 billion in revenue. (2S,3R,4R,5R)-6-Benzyloxy-2,4-bis-(tert-butyl-dimethyl-silanyloxy)-3,5-dimethyl-hexanenitrile vendor & factory Though the program obtained priority review from FDA back in November, analysts expressed skepticism in July 2020 after it failed to prove superior to the companies’ other drug Lumizyme in improving respiratory function in a Phase III trial.,In his new role, Grégoire will ensure alignment between NOVA’s business strategy, operations and growth objectives, as well as leading the Modelling and Simulation (M&S) team as NOVA embarks on its next phase of expansion.
